Skip to main content
. 2020 Jan 1;10(2):671–686. doi: 10.7150/thno.39863

Figure 11.

Figure 11

The inhibitory effects of CDots on NoV VLPs' binding to type A, B, O saliva HBGA receptors. (A) Type A HBGA; (B) Type B HBGA; (C) Type O HBGA. Different letters on the columns indicate significant differences at P<0.05, while any same letters on the columns indicate no significant difference. (Reprinted with permission from ref. 94